One urologist reaches his breaking point; are you next?
An astounding article in this issue of Urology Times details how oneurologist quit all commercial insurance participation, then "optedout" of Medicare-and is not only surviving, but thriving. Mike Harris, MD, a well-trained, board-certified, respected urologistin Traverse City, MI, said "Enough is enough!" and did somethingabout it. He no longer exists in any private insurance carrier databaseand likewise does not appear anywhere on the Medicare radar screen.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Jonathan E. Rosenberg, MD, discusses the FDA approval of perioperative durvalumab plus enfortumab vedotin and considerations for treatment selection in cisplatin-ineligible MIBC.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.